Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr. Vogelzang Discusses the Cabozantinib Trial Design

July 20th 2011

Dr. Nicholas J. Vogelzang from the Comprehensive Cancer Centers of Nevada Discusses the Cabozantinib Trial Design

Dr. Pruthi on the Flaxseed for Hot Flashes Trial Results

July 19th 2011

Dr. Sandhya Pruthi from the Mayo Clinic Explains the Flaxseed for Hot Flashes Trial Results

Trastuzumab and Chemotherapy Prolong Survival in Patients With Breast Cancer and CNS Metastases

July 18th 2011

Treatment with Herceptin, chemotherapy, or surgery extended the lives of patients with HER2-positive MBC following a diagnosis of CNS metastases.

Interim Safety Data Compared in Ixabepilone TITAN Trial

July 18th 2011

Researchers are continuing to explore whether ixabepilone (Ixempra) is a better choice as adjuvant chemotherapy for patients with early-stage, triple-negative breast cancer than the standard paclitaxel (Taxol).

Game-Changers: 11 Key Abstracts in ASCO Lineup

July 18th 2011

Abstracts presented at the 2011 ASCO Annual Meeting will have a major impact on both standard-of-care disease management and the future of clinical trials in multiple settings.

Dr. Tripathy on Breast Cancer with Bone Metastases

July 16th 2011

Dr. Debu Tripathy from USC Norris Comprehensive Cancer Center on Breast Cancer with Bone Metastases

Dr. Whelan Provides a MA.20 Trial Result Summary

July 14th 2011

Dr. Tim J. Whelan from Juravinski Cancer Centre Provides a MA.20 Trial Result Summary

BOLERO-2 Halted After Positive Interim Analysis

July 13th 2011

A phase III study of Afinitor (everolimus) tablets combined with exemestane in women with breast cancer revealed that the regime significantly extended PFS.

Study Shows Estrogen Not the Only Hormone Feeding Tumors in Breast Cancer

July 13th 2011

Although researchers know that estrogen plays a role in most cases of breast cancer, they don't fully understand how.

Dr. Whelan on the Women the MA.20 Trial Benefits

July 11th 2011

Dr. Tim J. Whelan from Juravinski Cancer Centre on the Percentage the MA.20 Trial Benefits

Dr. Whelan Discusses the MA.20 Trial's Survival Findings

July 8th 2011

Dr. Timothy J. Whelan from Juravinski Cancer Centre Discusses the MA.20 Trial's Survival Findings

Comorbid Conditions Threaten Breast Cancer Survivors

July 1st 2011

Breast cancer survivors age 66 and older are more likely to die of cardiovascular disease (CVD) than they are of the cancer itself.

ODAC Upholds Vote to Revoke Avastin's Breast Cancer Indication

June 29th 2011

An FDA advisory committee unanimously recommended Wednesday that the agency withdraw the breast cancer indication for Avastin.

Dr. Vogelzang Discusses Cabozantinib's Dose Size

June 29th 2011

Dr. NJ Vogelzang from the Comprehensive Cancer Centers of Nevada Discusses Cabozantinib's Dose Size

Study Reveals Disconnect Between Patient Treatment and Evidence-Based Guidelines

June 27th 2011

Nearly half of older women with advanced breast cancer in the United States failed to receive radiation following a mastectomy.

4 Questions for Martine Piccart-Gebhart, MD, PhD: Noted Breast Cancer Researcher Has Bright Hopes for HER2 Targets

June 27th 2011

Martine Piccart-Gebhart, MD, PhD is a professor of oncology at the Universite Libre de Bruxelles and director of the Medicine department at the Jules Bordet Institute in Brussels, Belgium.

FDA Roundup, Including Latest on Avastin Hearing

June 24th 2011

The FDA recently approved a new drug formulation, mandated label changes for cigarettes and sunscreens, and issued an opinion on breast implants.

HER2 Signaling Beckons: Dimerization Process, Combination Therapies Highlight New Research

June 24th 2011

The first drug that successfully targeted the HER2 pathway in cancer treatment generated much excitement.

Dr. Scher Discusses Circulating Tumor Cells

June 23rd 2011

Dr. Howard Scher form Memorial Sloan-Kettering Cancer Center Discusses Circulating Tumor Cells

PER Gatherings Focus on Breast, Lung Cancers

June 23rd 2011

Internationally known experts will discuss the latest research in breast and lung cancers at 2 conferences that the Physicians' Education Resource (PER) is hosting in California in August.